The consultation of the contents of this product is reserved exclusively for healthcare professionals

Magaldracid tablets

Bibliographic Evidence AvailableClass II AMedical Device

Medical device for the treatment of reflux diseases and may help reduce complaints linked to gastro-esophageal reflux (pyrosis, epigastralgia, acid regurgitation, retrosternal pain) and laryngo-pharyngeal reflux (coughing, dysphonia, odynophagia, laryngospasm, halitosis, asthma, dyspnoea, otalgia, rhinorrhea and nasal obstruction).

Magaldracid combines compoundr with antiacid properties and mucous-protective properties in a single formulation, to control the symptoms characterisic of gastro-esophageal and laryngo-pharyngeal reflux disease. Its effect is due to the presence of magaldrate, which neutralizes excess gastric acidity, magnesium alginate, which blocks the ascent of stomach acids, and a mixture of compounds (including hyaluronic acid), with adhesive, film-forming mucus properties that protect the mucous membranes from the effect of gastric acids. With just one product it is possible to act at several levels, by limiting gastric hyperacidity, impeding the passage of gastric acids towards the esophagus, trachea and larynx, and preserving the mucosa from the acid irritation that causes many complaints linked to acid reflux diseases.

24 chewable
1g tablets

Request Informations
Lactose free
Gluten free
OGM free